Evolent Health stock has a November 5, 2026 results date

Published on 10/17/2026 at 20:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

EVH sits 44.94 percent below its 52-week high on October 16, 2026. Evolent Health stock was last at EUR 4.11 in the German market that day.

Reporting date and valuation

Evolent Health is scheduled to report third-quarter results on November 5, 2026.
Evolent Health stock sat 44.94 percent below its 52-week high on October 16, 2026.
Evolent Health stock was last at EUR 4.11 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.
The company had a market capitalization of USD 514.0 million and a price-to-earnings ratio of minus 1.02 on October 16, 2026.

EVH, US30050B1017, Illustration mit AI erstellt.

Evolent Health has a scheduled reporting date of November 5, 2026, giving investors the next fixed checkpoint for the healthcare technology company. MarketBeat lists the third-quarter results before the market opens, with a conference call scheduled for 8:30 a.m. ET. On the NYSE, EVH last traded at USD 4.57 on October 16, 2026 at 4:00 p.m. ET, down 6.16 percent from the prior close. The last euro quote was EUR 4.11 at Lang & Schwarz on October 16, 2026 at 11:00 p.m. CEST.

Stock position within the yearly range

The USD 4.57 NYSE price stood 44.94 percent below the 52-week high of USD 8.30 and 117.62 percent above the 52-week low of USD 2.10 on October 16, 2026. That places the stock well inside its annual band rather than at either boundary. Trading volume reached 2,077,929 shares, compared with an average volume of 3,026,287 shares.

Valuation and November results

Evolent Health had a market capitalization of USD 514.0 million on October 16, 2026. Its price-to-earnings ratio was minus 1.02, while the dividend yield was 0.00 percent. MarketBeat identifies the listing as NYSE:EVH and reports an average analyst target of USD 5.96 based on 16 analysts.

Comparison with peers

Evolent Health: minus 6.16 percent, P/E minus 1.02, market capitalization USD 514.0 million
Teladoc Health (NYSE, USD): minus 5.03 percent, P/E minus 5.73, market capitalization USD 1.0 billion
Privia Health Group (NASDAQ, USD): minus 0.44 percent, P/E 103.83, market capitalization USD 2.9 billion

What the next date adds

The November 5, 2026 report will put the company's third-quarter performance next to the market's current valuation. The scheduled date is the clearest near-term calendar marker, while the negative price-to-earnings ratio reflects the company's earnings position at the October 16 close.

Euro quote and market view

The last available Lang & Schwarz indication was EUR 4.11 on October 16, 2026 at 11:00 p.m. CEST. The NYSE session had ended at USD 4.57, with the stock down 6.16 percent on the day. The further course of trading is shown by the continuously updated real-time quote of Evolent Health stock.